☆ 4.6 Article

27523 Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis (AD) from the phase 2 and phase 3 clinical trial program

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Volume 85, Issue 3, Pages AB150

Publisher

Elsevier BV

DOI: 10.1016/j.jaad.2021.06.615

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

27523 Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis (AD) from the phase 2 and phase 3 clinical trial program

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Publisher

Elsevier BV

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

27523 Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis (AD) from the phase 2 and phase 3 clinical trial program

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Publisher

Elsevier BV

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper